BD Spinal Tray Recall Due to Bupivacaine Quality Issues
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Becton Dickinson & Company is recalling 990 units of BD Spinal Tray with BD Quincke Needle due to quality issues with the included bupivacaine from Huons Co, Ltd.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on July 10, 2026 and geographically references United States. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, Devices.
What Happened
Becton Dickinson & Company initiated a voluntary recall of the BD Spinal Tray because it is a sub-recall of a product from Huons Co, Ltd., the manufacturer of Bupivacaine Hydrochloride in Dextrose Injection, USP. The recall is due to quality issues identified during an FDA manufacturing facility inspection, citing specific quality deficiencies related to acceptance testing.
Which Products Are Affected
The affected product is BD Spinal Tray with BD Quincke Needle 22 G x 3.5 in.; lidocaine HCL (1%), 5 mL, bupivacaine HCL (0.75%) with dextrose (8.25%), 2 mL (marcaine). Catalog Number: 405609. UDI Numbers: (10)00382904056094(17)261001(10)B01V212D, (10)00382904056094(17)270101(10)B01V238D. Lot Numbers (Expiration Date): B01V212D (2026-10-01), B01V238D (2027-01-01). A total of 990 units were distributed nationwide to AK, AL, AR, AZ, CA, CO, CT, FL, GA, IA, IL, IN, KS, KY, LA, MA, MD, MI, MO, MS, NC, NE, NH, NJ, NV, NY, OH, OR, PA, PR, SD, TN, TX, UT, VA, WA, WI, WV, WY. Recall number Z-2248-2026. Classification: Class I.
What You Should Do
Consumers should refer to the recalling firm or FDA for guidance on the recall.
Why This Matters
This Class I recall involves 990 units distributed nationwide and stems from identified quality deficiencies in an essential component.
Source
FDA recall number Z-2248-2026, event ID 98842.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,369 characters here).
Similar severity timing
Same severity (high) notices issued closest in time to July 10, 2026.
Frequently Asked Questions
Common questions about this FDA recall.